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Abstract
Background: Pivotal trials have established that, among people who have no immediate intention to quit smoking,
nicotine replacement therapy (NRT) helps people reduce and eventually stop smoking. The prime aim of this trial
was to investigate the feasibility of implementing such a programme in community pharmacies. In addition, we
investigated the effectiveness of providing behavioural support compared with self-help methods and of shorter
compared with standard length reduction programmes.
Methods: Pharmacists were trained to deliver a smoking reduction programme and opportunistically invite people
to participate in the programme. In a 2 × 2 factorial design, eligible volunteers were randomised to either receive
in-person behavioural support or a self-help booklet. In both cases, participants were supported to set targets to
reduce their smoking and use behavioural techniques to assist reduction. In addition, participants were randomised
to cut down and stop over 4 weeks or over 16 weeks, but in either case continue NRT for up to nine months. We
assessed uptake and adherence to the programme and smoking cessation four weeks and six months after a quit
day and reduction in the three months following programme end and incorporated a qualitative processes assessment.
Results: Only 68 of the planned 160 smokers could be recruited. Pharmacists were deterred by the bureaucracy of trial
enrolment and that many smokers did not return for further support. Pharmacists sometimes subverted the randomisation
or provided support to participants in the self-help arm. Smokers stayed in the programme for an average of 6 weeks
rather than the 9 months envisaged. Rates of follow-up declined to around 20% of participants by 12 months. There was
insufficient evidence to assess whether support or speed of reduction enhanced cessation or reduction but cessation and
reduction were less common overall than in the pivotal trials for licensing NRT for this indication.
Conclusions: This programme of smoking reduction and the trial design to assess its effectiveness proved unpopular to
potential participants and pharmacists. As a result, the trial produced no evidence on the effectiveness of behavioural
support or speed or smoking reduction. A trial of this programme in this context is unfeasible.
Trial registration: ISRCTN 54805841. Registered 18 March 2010.
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Background
Historically, treatment of tobacco addiction has focused
on facilitating smokers to quit abruptly. However, in the
UK, in population based surveys of smokers, around
90% say they are not prepared to set a quit day, whereas
around half are actively cutting down [1]. In 2012, the
English Smoking Toolkit survey found that 53% of
current smokers were cutting down, and 26% of re-
ducers were using nicotine replacement therapy (NRT)
to assist this [1]. In the UK, a network of specialist
smoking cessation services provided in part by GP prac-
tices and pharmacies support smokers to quit abruptly
[2]. Although this service has been shown to be effective
[3], the rate of access is low. It is possible that diversify-
ing the approaches available to smokers to quit may en-
courage more people to use specialist support. However,
reduction programmes are not routinely offered as part
of standard care.
There is evidence that smokers who use NRT and are
supported to reduce are more likely to achieve lasting
abstinence than smokers using placebo but receiving
support [4, 5]. This provides proof of principle that sup-
porting reduction enhances and does not deter abstin-
ence in those who join such programmes. However, it
leaves open the possibility that advertising smoking re-
duction as an option may deter people from quitting
altogether. The evidence does not suggest that this is
likely [6], but it remains uncertain. There is no strong
evidence that behavioural support improves the rate of
abstinence when offered for smoking reduction pro-
grammes [7]. Most studies showing NRT is effective
have incorporated behavioural support but studies with
minimal support also suggested NRT alone is effective
[8, 9]. However, there is good evidence that behavioural
support increases efficacy of abrupt cessation pro-
grammes by between 50–100% so it is possible that it
improves success in reduction programmes [10, 11]. In
this feasibility trial we examined preliminary evidence
that behavioural support might be effective for smoking
reduction.
The trials that led to the licence change allowing to be
used for reduction asked participants to follow a nine-
month reduction programme, albeit aiming to achieve a
50% reduction by 6 weeks.
However, there is also evidence to suggest that pro-
grammes of reduction over shorter periods of time may
be more effective [12]. We also used this trial to examine
preliminary evidence of this.
The aim of offering reduction services is to lead to
more people attempting to quit and using support to do
so. If even a small fraction of the 50% of smokers that
are currently reducing their smoking choose to take up
reduction support, the demand for services would be
very great. Meeting this demand would require drawing
upon the generalist workforce. Many pharmacies offer
specialist cessation services already. In addition, they sell
NRT, much of it for smoking reduction, and therefore
they are ideally placed to offer a reduction service, but it
is unclear how attractive this will be to the population
and how competently these may be delivered and what
proportion of people will go on to quit. The main aim of
this trial therefore was to test the feasibility of pharma-
cists opportunistically recruiting smokers and running
nicotine assisted smoking reduction programmes.
Methods
The protocol for this study has previously been pub-
lished [13]. The main aim of the study was to assess the
feasibility and take-up of the programme. However, we
also investigated two factors in a 2 × 2 randomised fac-
torial trial: the speed of the reduction programme (short
v standard length programme) and the value of behav-
ioural support (behavioural support v self-help). Ethical
approval for this study was granted by Birmingham East,
North and Solihull Research Ethics Committee on 14th
June 2010 (REC reference number: 10/H1206/22).
Pharmacies were eligible to participate if they were
currently running a NHS specialist smoking cessation
service. Pharmacists and their teams, were trained twice
for two hours to deliver the programme. Training in-
cluded an introduction to why the trial was necessary,
discussion of randomisation, familiarisation with the
principles of reduction programmes, and also detailed
the practicalities of all the stages of delivering the inter-
vention programme and research methods from oppor-
tunistic recruitment through to the final participant
visit. Pharmacists also practised their skills in recruit-
ment and intervention delivery through participating in
role plays.
Participants
Pharmacists aimed to recruit smokers aged 18 and
over who were not planning to quit smoking within
the next 4 weeks but who were wanting to reduce
consumption, with or without intention to stop com-
pletely. They informed participants about the study
and participants signed a consent form. Participant
eligibility criteria were:
(1)Daily smoker with an exhaled carbon monoxide
(CO) reading of at least 10 parts per million (ppm)
at least 15 min after last cigarette smoked, or smoking
at least 10 cigarettes or 8 g of loose tobacco as self-
rolled cigarettes daily.
(2)Able to be followed up by either telephone or email.
(3)Not currently using pharmacological, behavioural or
alternative therapies for tobacco dependence.
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(4)No illness that would increase the risk from concurrent
use of NRT while smoking
(5)Not pregnant, breast feeding or intending to get
pregnant in the next 9 months
(6)No severe acute or chronic medical or psychiatric
condition that may increase risk associated with
study participation due to concurrent smoking and
NRT use or may interfere with the interpretation of
study results. Most people with medical or psychiatric
conditions were included.
Pharmacists were trained to identify potential partici-
pants opportunistically; they were also encouraged to
use other recruitment methods such as approaching
those who had tried but failed to quit smoking previ-
ously. To facilitate recruitment, pharmacies were
supplied with a poster to advertise the reduction
programme. In addition to the initial training, the study
team also telephoned and visited the pharmacies to keep
up motivation and to address barriers or concerns about
approaching smokers and the treatment programmes.
We also visited local general practices to raise awareness
of the study and to encourage GPs to refer patients who
were reluctant to quit smoking to a local participating
pharmacy. GPs were given referral cards with the details
of the study and details of participating pharmacies to
enable this process. In the final phase of the study GPs
wrote to their patients who smoked offering reduction
programmes.
Interventions
The primary aim for the reduction programme was for
participants to reduce their daily cigarette consumption
by at least 50%, but participants could transfer to a
smoking cessation programme at any point during the
reduction if they wanted to quit.
Participants were randomised to two conditions. In
one condition, participants were randomised either to
receive behavioural support or provided with self-help
resources to guide them to achieve the same reduction.
In the other condition, participants were randomised to
reduce consumption rapidly, halving consumption by
two weeks, compared with the standard reduction
schedule, halving consumption by six weeks.
Behavioural support vs self-help
In the behavioural support arm, pharmacists explained
the rationale for the programme by suggesting that
learning a new pattern of smoking would prevent con-
sumption increasing again by disrupting learnt associa-
tions between cues and smoking behaviour. They
encouraged participants to use NRT and choose one of
three methods of reduction, called the “timer method”,
“smoke-free periods”, or “unstructured”. In the timer
method, participants used a timer, such as a mobile
phone, to signal when they could smoke and agreed to
smoke only when the timer indicated it was appropriate
to do so. This time lengthened on each occasion a per-
son wanted to reduce. The smoke-free periods method
divided the day into hours and participants progressively
eliminated hours, agreeing not to smoke in the hours
participants designated smoke-free. In the unstructured
method participants were free to smoke when they liked
but to set aside each day’s cigarette ration in a pack. We
encouraged pharmacists to use either of the structured
methods in preference because there is evidence that
they are more effective [14].
In the behavioural support arm, participants returned
to the pharmacy for eight occasions after baseline for
support. We envisaged pharmacists spending around
10 min on support on each occasion.
In the self-help arm, the smoking reduction methods
were exactly the same as above, but they were explained
in a written booklet. We asked pharmacists to hand out
the booklets without further advice or interaction.
In the behavioural support arm, pharmacists enquired
about participant’s willingness to quit smoking at each
visit and transferred a person ready to do so to a stand-
ard smoking cessation programme. In the self-help con-
dition, the booklet prompted the reader to consider this.
Short vs standard length reduction programmes
Both programmes contained 8 steps, whether offered in
conjunction with a self-help booklet or with support
from the pharmacist. Initially, we asked participants to
try to reduce consumption by a quarter, then by a half,
then three quarters to achieve abstinence by the fourth
step. In the short programme, this was scheduled to take
four weeks, in the standard programme 16 weeks. The
pattern of visits in the standard condition was scheduled
as baseline, 2, 6, 10, 16, 22, 28 and 34 weeks, and in the
short condition as baseline, 1, 2, 3, 4, 6, 8 and 16 weeks,
with the first four visits marking a step with a new re-
duction goal if the last had been achieved. If a partici-
pant did not want to achieve abstinence at the
designated point in the programme (i.e. at 4 or 16 weeks)
then the additional visits were to motivate further
attempts at reduction and/or cessation.
Adjuvant pharmacotherapy
In all treatment conditions, participants were prescribed
NRT throughout the programme. Pharmacists encour-
aged participants to use both a nicotine patch and a
short acting form of NRT (2 mg gum, 2 mg sublingual
tablets, 2 mg lozenge, inhalator or nasal spray) and to
continue using NRT regardless of their success in reduc-
tion, unless they had moved onto a cessation pathway
and had successfully quit. The protocol specified that
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participants smoking less than 10 cigarettes per day
(cpd) should be prescribed 7 mg/24 h or 5 mg/16 h
patches, 10–19 cpd 14 mg/24 h or 10 mg/16 h patches
and 20+ cpd were prescribed 21 mg/24 h or 15 mg/16 h
patches. Participants were advised to replace each ‘miss-
ing’ cigarette with use of one dose of their chosen short
acting product. The rationale for this regimen is de-
scribed in the trial protocol [13]. All participants were
encouraged to use NRT for 9 months regardless of
intention to reduce or stop, or failure of either reduction
or cessation.
Randomisation sequence generation, allocation concealment,
implementation
The research team generated the randomisation se-
quence using a computer algorithm at http://www.ran
domization.com, and the allocations were given to phar-
macists in numbered, sealed envelopes. Block random-
isation stratified by pharmacy was used to generate the
sequence, with two randomly ordered blocks of four and
one of eight. This ensured balance of participants within
a pharmacy. Participants were randomised with a ratio
of 1:1 for both of the two conditions.
Follow up and blinding
Data on reduction or cessation were collected by phar-
macists when participants visited the pharmacy for study
visits. Regardless of whether participants visited the
pharmacy we assessed cigarette consumption, NRT use,
and cessation each month by email containing a link to
an online questionnaire. We elected to use an online
questionnaire to reduce the sense that the participant
was being monitored by a caring person which could
have inadvertently provided behavioural support. Two
reminders were sent to participants that did not
complete the questionnaire, after which participants
were telephoned. Participants who claimed abstinence
for either 4 weeks or 6 months were asked to attend the
pharmacy for carbon monoxide verification and were
compensated £20 for doing so.
It was not possible to blind pharmacists or participants
to the treatment allocation. However, the telephonists
conducting the monthly follow up calls and hence the
person assessing the outcome assessor was blind to
treatment arm.
Qualitative interview data collection
Semi-structured interviews were conducted with 10
pharmacists at the end of the study to investigate key
barriers and facilitators to opportunistic recruitment and
implementing the reduction programme, and their over-
all response to the programme and trial. Pharmacists
chosen for interview reflected both those who had re-
cruited many and few participants. Semi-structured
interviews were also conducted with trial participants,
with purposive sampling from each trial arm of partici-
pants who dropped out, reduced or quit smoking. These
interviews covered participants’ motivation for agreeing
to participate, participants’ views on how participating in
the programme had affected their smoking, why they felt
their smoking had been affected, and also their experi-
ence of participating in the trial, including the monthly
follow up. Interviews were audio-recorded, transcribed
and anonymised before analysis.
Outcomes
The main outcomes assessed the feasibility of imple-
menting the reduction programme in pharmacies, and
estimated important parameters necessary for designing
a definitive trial. These included: (1) the percentage of
pharmacists approached that agreed to participate and
percentage of participating pharmacies that passed an
assessment of competence; (2) monthly recruitment
rates of smokers onto the reduction programme; (3) pro-
portion of smokers who moved onto a cessation pathway
or who dropped out; (4) quantitative description of fidel-
ity of the pharmacist to the treatment conditions; (5) the
number of people that completed the monthly question-
naire follow up, and the number contacted by telephone;
(6) the amount of NRT used by trial arm; (7) number of
adverse events and (8) the proportion of participants that
would recommend the smoking reduction programme to
another smoker.
Qualitative process outcomes included: (1) qualitative
description of fidelity to the protocol of pharmacist-
delivered behavioural support sessions; (2) pharmacists’
views regarding the design and running of the
programme; (3) participants’ (smokers’) views regarding
the design and running of the programme.
In addition, we collected efficacy outcomes defined as
biochemically confirmed “floating” sustained abstinence
for four weeks. Sustained abstinence was defined using
the Russell standard definition of prolonged abstinence
i.e. self-report abstinence or up to five cigarettes smoked
only, from day 15 after quit day onwards [15]. The be-
ginning of the period of sustained abstinence could be at
any time (i.e. floating) during the time a participant was
in the study [16]. Self-report abstinence was biochem-
ically validated if the participant’s exhaled breath had a
CO concentration of less than 10 ppm.
Secondary efficacy outcomes were biochemically con-
firmed prolonged abstinence measured at six months,
self-reported abstinence at four weeks or six months,
and sustained smoking reduction. Smoking reduction
was measured in the three ways: (1) self-report reduction
in daily cigarette consumption to <50% of baseline value
sustained between months 9–12 after baseline; (2) self-
report daily cigarette consumption lower than baseline
Farley et al. BMC Public Health  (2017) 17:210 Page 4 of 15
consumption by any amount which was sustained be-
tween 9–12 months after baseline; (3) mean difference
between baseline and 12-month daily cigarette con-
sumption. For (1) and (2), if one middle datum point
was missing, but all others showed <50% reduction, this
was counted as a sustained reduction. If the end data
point or more than one data point was missing, this was
not counted as sustained reduction. For (3), if 12 month
follow up data was missing, this was imputed as baseline
daily consumption. A sensitivity analysis was also per-
formed using last observation carried forward.
Sample size
Given that the objective of this study was to test feasibil-
ity, the trial was not powered to provide definitive evi-
dence of the effectiveness of one reduction programme
versus another. The most important outcome in terms
of health is proportion of participants who move on
from the reduction programme to quit. We calculated
that 160 smokers (16 patients per pharmacy) would pro-
vide sufficient power to detect plausible differences be-
tween arms in abstinence rates at 4 weeks. Our
previously published systematic review showed that in a
standard length reduction programme, 7% of partici-
pants sustain abstinence at 6 months [4]. This would
equate to about 21% achieving 4 weeks abstinence. A
previous trial suggested that shorter reduction pro-
grammes are about twice as effective as standard length
programmes [12]. Based on these estimates, a sample
size of 160 would have 80% power to detect a risk ratio
of 1.7 or 90% power to detect a risk ratio of 1.8, which is
lower than that observed in the Haustein trial [12]. We
also considered that this sample size would be sufficient
to explore the additional process outcomes. For example,
if attendance for behavioural support session was 63%
(as observed in our review [4], with 80 smokers receiving
behavioural support, we could estimate this with
+/−11% precision with 95% confidence.
Statistical methods
Quantitative process measures were analysed using
standard descriptive statistics, and compared by trial
arm where appropriate. Relative risks and risk differ-
ences with 95% confidence intervals were calculated to
compare efficacy outcomes (i.e. sustained cessation or
reduction), between trial arms. As we stratified the ran-
domisation by pharmacy, we accounted for this in a gen-
eralised linear mixed model, with pharmacy set as a
random effect to allow generalisation and treatment
arms as fixed effects using a logit link function and ro-
bust covariance matrix. These analyses were conducted
as an intention-to-treat analyses, where participants with
missing data were assumed to be smoking or to have not
reduced, and all participants randomised to a condition
were included in the denominator. To compare continu-
ous outcomes between trial arms (i.e. mean daily
cigarette consumption), we calculated the difference in
means and compared these using a t-test. We planned
to conduct multi-level modelling examining whether the
availability of a reduction programme increased or de-
creased the number of people attempting to stop smok-
ing in the pharmacies; however, we were unable to
obtain the necessary data from the local stop smoking
services.
Qualitative data generated from the semi-structured
interviews were analysed using thematic analysis.
Themes were derived deductively from the aims of the
interview, and also arose from the interview data.
Results
The original intention was for 10 pharmacies to each re-
cruit 16 people in four months, which all agreed was a
feasible target. In the event, participant recruitment fell
way short of this so we recruited another batch of phar-
macies. Altogether, we approached 27 pharmacies of
which 18 (66%) agreed to participate. Pharmacists all
attended both training sessions and demonstrated suffi-
cient competency during role playing to be considered
successfully trained. There were a total of 68 participants
recruited into the study between Dec 2010 and Sept
2012 (Fig. 1). Several initiatives were instigated through-
out recruitment to boost recruitment; however, this final
figure did not meet the recruitment target.
Quantitative process measures
Monthly recruitment rates and randomisation
A median of one (range 0–12) participants were re-
cruited each month (see Fig. 2). GP mailings to smokers
to encourage them to join the programme recruited few
additional participants.
Baseline characteristics
Low recruitment meant that the block randomisation
did not produce perfect balance and there were imbal-
ances in the characteristics of participants across study
conditions at baseline, particularly for gender, ethnicity,
number of cigarettes smoked per day, and the partici-
pants’ reasons for wanting to cut down (Table 1).
Fidelity to randomisation
There was evidence that pharmacists did not follow ran-
domisation protocols. We discussed the necessity for
randomisation at the training, although it was clear that
pharmacists believed strongly that their support was es-
sential. In both cases of duplicate enrolment, pharma-
cists opened a second envelope in order to offer
behavioural support.
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Fidelity of the pharmacist to the treatment conditions
Participants allocated to behavioural support were ran-
domised to receive sessions over a standard length
schedule (0, 2, 6, 10, 16, 22, 28 or 34 weeks) or a short
length schedule (0, 1, 2, 3, 4, 6, 8, 16 weeks). The median
number of weeks after baseline (Visit 1) that participants
returned for behavioural support was similar to these
schedules specified in the protocol. However, the range
was large, and for some participants the behavioural
support plan was not adhered to (Table 2).
Pharmacists were asked to set a reduction target with
participants in the support arm to achieve by the next
meeting and did so in a median of 92%, (range 33,
100%) of participants who attended Visits 1–8). Pharma-
cists were asked to discuss a reduction method with par-
ticipants and record this and did so in a median 89%
(range 45, 100%) of participants who attended Visits
1–8 (Table 3).
Contamination in the self-help arm
Participants randomised to the self-help conditions
should not have received behavioural support when
returning to collect further NRT prescriptions. However,
there was evidence that pharmacists were routinely re-
cording reduction targets, setting new reduction targets,
and less commonly recording reduction methods used
Fig. 1 Study flow
Fig. 2 Monthly (bar) and cumulative (line) recruitment rates over the study period. Arrows indicate timing of recruitment drives
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Table 1 Participant baseline demographic and smoking characteristics
Behavioural/Standard
n = 17
Self Help/Standard
n = 17
Behavioural/Short
n = 19
Self Help/Short
n = 15
Age yrs, mean (SD) 44 (12.3) 44 (16.5) 44 (12.0) 43 (13.1)
Male, n (%) 11 (65) 7 (41) 6 (32) 10 (67)
Ethnicity, n (%)
White 7 (35) 8 (47) 11 (58) 6 (40)
Other 9 7 5 7
Missing 0 0 0 1
Age started regular smoking, mean (SD), n 16 (3.0), 16 17 (5.0), 14 16 (2.3), 16 17 (2.6), 14
Have you ever made a serious quit attempt, n (%)
Yes 12 (71) 12 (71) 12 (63) 11 (73)
No 4 (24) 2 (12) 4 (21) 3 (20)
Missing 1 (5) 3 (17) 3 (16) 1 (7)
FTND, mean (SD) 5 (2.3), 16 6 (1.7), 15 6 (2.8), 16 6 (2.5), 14
Cigarettes per day, mean (SD) 17 (8.2) 23 (8.2) 20 (9.1) 17 (6.5)
CO, mean (SD), n 17 (8.4), 17 19 (11.2), 17 19 (10.4), 18 17 (8.7), 15
Reasons for cutting down, n (%)
I want to cut down as a way to stop 9 (53) 8 (47) 10 (42) 11 (73)
I want to cut down as a way to smoke less 7 (42) 7 (41) 6 (32) 3 (20)
I’m not sure why I want to cut down 0 (0) 0 (0) 0 (0) 0 (0)
Missing 1 (5) 2 (12) 3 (16) 1 (7)
Highest educational qualification
Secondary school (up to age 15/16) 7 (41) 4 (24) 7 (37) 6 (40)
Sixth form (up to age 18/19) 4 (24) 2 (12) 1 (5) 1 (7)
Professional or technical qualification/diploma after school 0 (0) 1 (6) 1 (5) 0 (0)
University/polytechnic degree course 0 (0) 2 (12) 0 (0) 1 (7)
Still in full time education 1 (6) 2 (12) 2 (11) 3 (20)
None of the above 4 (24) 4 (24) 5 (26) 3 (20)
Missing 1 (6) 2 (12) 3 (16) 1 (7)
Table 2 Fidelity to standard and short behavioural support schedules
Behavioural Support/Standard
n = 17
Behavioural Support/Short
n = 19
n
attending
Week after baseline as
specified by protocol
Actual attendance time
(weeks) median (range)
n
attending
Week after baseline as
specified by protocol
Actual attendance time
(weeks) median (range)
Visit 1 17 0 0 19 0 0
Visit 2 11 2 2 (1, 6) 15 1 1.3 (1, 9)
Visit 3 9 6 5.4 (2, 9) 12 2 2.1 (2, 17)
Visit 4 8 10 9.4 (3, 48) 10 3 3.4 (3, 7)
Visit 5 7 16 14 (4, 52) 7 4 5 (4, 8)
Visit 6 6 22 21.7 (5, 59) 5 6 7 (6, 11)
Visit 7 4 28 27.4 (6, 64) 5 8 8.7 (7, 18)
Visit 8 2 34 7.5 (7, 8) 4 16 17.5 (11, 27)
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in the self-help participants, suggesting that they were in
fact providing support (Table 3).
NRT use
The protocol advised use of NRT for up to 9 months as
long as participants were continuing to try to reduce.
However, participants were prescribed NRT for a much
shorter time, which was similar in all arms (median
(range) months: short 1 (0.25–13), standard 1.75 (0.25,
15)), behavioural 1.25 (0.25–15), self-help 1 (0.25–14).
Six participants were prescribed NRT for longer than
9 months (up to 15 months).
Fifty-eight of the 68 (85%) included participants were
prescribed patches. Participants in each arm were pre-
scribed a similar number of patches per month, and the
median number prescribed was similar to the recom-
mended amount (median (range) patches/month: short
28 (3–28), standard 26 (2–29), behavioural 28 (2–29),
self-help 26 (7–29)). Forty four participants using
patches were also prescribed a median (range) of 1 (1–3)
additional short-acting NRT product. Participants used
inhalators, lozenges, gum, microtabs, mints, nasal spray
and minis, and the most popular oral product was the
inhalator.
Follow-up
Most participants did not complete the online ques-
tionnaire and instead monthly follow up was con-
ducted by telephone. The percentage of participants
successfully contacted each month fell steadily in all
trial arms, with 18, 24, 26 and 13% being followed up
at 12 months in the behavioural/standard, self-help/
standard, behavioural/short and self-help/short groups
respectively (see Fig. 3).
Qualitative process measures - pharmacists
Ten pharmacists were interviewed at the end of the trial
about their views about the programme, and barriers/fa-
cilitators to recruitment to the trial and participation in
the reduction programme. There were no clear differ-
ences in the themes emerging from pharmacists who
had been able to recruit patients and those who had not.
Views about the programme (Table 4)
All pharmacists felt that the reduction programme
was good in principle, and that participating in the
study would be a good opportunity to extend the
smoking cessation services already successfully of-
fered by the pharmacy. Pharmacists felt that the
programme was useful because it would offer a less
strict option to cessation and would suit patients
who had not been able to quit using the cessation
service or for heavy smokers who may not feel able
or ready to quit. In this way, they had anticipated
Table 3 Number of participants in behavioural and self-help arms who had a target and method recorded.
Behavioural
n = 36
Self Helpa
n = 32
Visit n Last visit target met
n (%)
New target set n (%) Method recorded
n (%)
n Last visit target met
n (%)
New target set n (%) Method recorded
n (%)
1 36 31 (86) 36 (100) 32 9 (28) 23 (72)
2 26 26 (100) 26 (100) 24 (92) 17 8 (47) 10 (59) 10 (59)
3 21 21 (100) 18 (86) 19 (90) 14 7 (50) 2 (14) 6 (43)
4 28 18 (100) 17 (94) 16 (89) 9 4 (44) 2 (22) 4 (44)
5 14 14 (100) 13 (93) 13 (93) 7 5 (71) 1 (14) 2 (29)
6 11 11 (100) 11 (100) 5 (45) 5 4 (80) 2 (40) 2 (40)
7 9 9 (100) 8 (89) 7 (78) 4 4 (100) 0 (0) 1 (25)
8 6 6 (100) 2 (33) 4 (67) 3 3 (100) 0 (0) 0 (0)
aParticipants randomised to self help should not have undergone a review of their previous targets, setting of a new target or discussed method of smoking reduction
with the pharmacist. However, there was evidence that this was done in a large proportion of these participants
Fig. 3 Monthly percentage follow up rates by trial arm
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that by participating in the programme, they would
be able to reach more of their patients who found it
difficult to quit smoking abruptly. Only one pharma-
cist expressed concern that a reduction programme
may divert smokers away from quitting, and he be-
lieved that it was important to be clear to partici-
pants at the start of a reduction programme that the
purpose was to cut down in order to quit.
Most pharmacists reported that they preferred offer-
ing behavioural support rather than the self-help
programme. Behavioural support was seen to be more
satisfying, pharmacists believed it would be more ef-
fective and did not feel comfortable assigning patients
to self-help. Generally, pharmacists had no strong
views on the behavioural methods to help people re-
duce. However, some felt that the timer method was
not feasible, with one pharmacists suggesting that it
might be counter-productive to encourage people to
smoke when it was the correct time to do so. Some
felt that smoke free periods or unstructured methods
were more popular and practicable.
Recruitment methods (Table 5)
Pharmacists main recruitment approach was to target
people that they had tried to help to stop smoking
abruptly and who had failed. They also described offer-
ing the programme to patients who asked for help to
stop smoking, bought nicotine replacement therapy or
had seen poster advertisements in the window of the
pharmacy or at their local general practice and enquired
about the programme. Although pharmacists and their
teams were trained to broach the subject of smoking re-
duction opportunistically with customers whom they
knew smoked, only one pharmacist described using this
technique.
Barriers to recruitment and continued engagement with the
programme (Table 6)
Pharmacists described several barriers to successful re-
cruitment and engagement with the programme.
Desire to reduce
Most pharmacists reported that when they offered pa-
tients a choice between joining the smoking cessation
programme or the reduction programme, patients chose
cessation rather than reduction.
Table 4 Attitudes towards the reduction programme – illustrative
quotes from pharmacists
“I think people don’t come at the moment because they think that they’re
going to be pressurised… you know and a lot of finger pointing…so I
think it is a good idea to have a programme that… allows very heavy
smokers…to reduce first, before they quit, and that might help them more.
” PH01
“I think there is definitely a place for it…it would be able to help a lot
more people than I was presently because the stop smoking services is very
strict really… whereas at least with [the reduction programme] they can
approach it gradually” PH06
“I think it’s quite important to establish that when you set out with a
reduction scheme, you’re on…what I think is dodgy grounds because the
patients thinks… “well I can reduce…and they don’t, they don’t see that
final goal as quickly, whilst the cessation scheme is more likely… I think
just as long as…it’s set out from the beginning that you’re going to reduce
to quit, then I think…it can be valuable part of the NHS.“ PH15
“With the Self Help… I think it just depends on the person…how much
enthusiasm they’ve got for it…if they’ve got… to do it themselves and
make their own decisions, I don’t think that motivated them at all“ PH04
“I think it’s the smoke free period without a doubt [that is the best approach].
The timer method is only suitable for, very small proportion of the population.
And even then, it doesn’t actually deter people, it might actually work the
opposite way, and people may be used to then smoking every hour. Or every
hour and a half, they make it the habit, that, ‘Oh God… I need to smoke
now.” PH07
“When you are helping the person, behavioural support, it was more
satisfying than…just tell them to go… do it themselves…”PH10
“I think, the one to be left on their own to do everything would have
been…not appropriate, I think they really needed the support.”PH12
“It was a very thin line between ‘I am giving you support now,’ where ‘I’m
not giving you support now.’ Now where do you stop, giving that
support…You can even sit down with the guy and say, yeah try here, try
here, do this, like we do with NRT product. But you can’t give him
support…it’s a very thin line between, now I’m giving him support… and
kind of messing with the study, where does my role stop, where can I say,
nope, I can’t give you any more support past this point.” PH16
Table 5 Recruitment methods - illustrative quotes from
pharmacists
“People that came in and inquired about smoking patches and… inquired
about what they could do for smoking, I would offer them [the reduction]
programme alongside the [cessation] programme” PH01
“We’ve had the posters around the window, we’ve tried moving it about to
different locations thinking it would maybe catch their eye better at
different locations, we’ve also when people come into enquire about stop
smoking we do ask them would you like to cut down or are you looking to
just… quit altogether” PH2
“I know there was one GP he would send these letters out…we only got
like four people ring us out of the whole lot. And only…one of them
turned up out of the four. So, it just didn’t get people on as much as you’d
hoped.” PH04
“We put up a poster in all the waiting rooms in surgeries, we put posters
up in pharmacy, and people who were coming in, we were asking them if
they wanted to give up smoking or did they want to reduce smoking. So,
those are the main [recruitment] methods we used.” PH06
“We get a lot of referral from our GP, as well as…approaching patients… I
gave it as a dual option, they could go for? the reduction method or they
could go for the straight NRT approach.” PH08
“the record I keep of the, over the years of stop smoking service, I rang
them up and I said, were they still smoking and, would they be interested,
and also when we had some customer who came in and we asked them
would you like to join this programme, when they bought a prescription
and we’d normally ask them if they smoke, or even if they buy a cough
mixture ….we targeted about fifteen people.. all of them, declined…we
gave out lots of cards… I dropped it in the local surgeries as well but we
didn’t get anything back from the surgeries. No referrals or nothing.” PH10
“we tried as much as possible to promote it, the posters and the little cards
inside the things and stuff… it was mainly just anybody who…came to us
to say that they noticed the poster … I say ‘look we offer two schemes…
there’s one that you can…just … cut down, or there’s one that you can
stop altogether, what would you prefer” PH15
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Table 6 Barriers to recruitment and continued engagement –
illustrative quotes from pharmacists
“the initial consultation takes a bit of time… and because people haven’t
been on this programme before, it’s a lot of information to go through
whereas the other form [for cessation], a lot of people come in and re-sign
up… it’s been running for years so they know all about it, and this is new
so, they’ve just a bit more time to get their head around it and explain
everything to them and get my head around it as well…What I don’t like
about it at the moment is the fact that the whole paperwork and the
structure for it is different to the other service…[if] the paperwork was similar,
it would be a lot easier… this is all quite new and then… you’re slapping
around trying to get the different paperwork and sometimes I think you… just
leave it to the patients to come back…if I could… get an appointment from
them there and then and get a telephone number…I think that maybe
would’ve been a better thing to do. ”PH01
“I think when you try and explain the structured method to them…
smoking every so many minutes…I think they look at you a little bit
funny… I think they expect to go on the programme and just use the
programme to reduce the number of cigarettes themselves and then when
you sit and explain all the structure to them it sort of baffled them a little
bit” PH01
“I think because of the staffing issues as you’ve seen and the fact of the
length of the interviews as well for the first few appointments that’s
probably a put off… but with a lot of our patients they’ve not really
actively come in and seek to cut down, I think when they come in they’ve
made up their minds they want to quit, they want to go all the way… so I
think that’s probably the biggest hurdle we’ve had.” PH02
“It was hard to get people on. … they know there is a stop smoking
course, and they will come because they want to stop smoking today, but I
don’t think a lot of people wake up saying, “I want to cut down…I did ask
people, even the people that came in… “Oh, I want to stop smoking” I’d
tell them that we were doing the reduction or to stop smoking and they
say, “I want to stop smoking, not the reduction.” PH04
“I mean, the cessation programme is short and you have to stop by the
second week; whereas this, you get people who go up and down, up and
down over the longer period, you know…I think if they had like a barrier,
say, ‘By this time you have to have stopped or cut down to this much’,
then, I think they will try a bit harder…they knew that they can go up and
down and you know it wouldn’t really matter, I think that’s when that
probably took advantage of.” PH04
“During the period that it was running we actually managed to recruit
about ten people into the stop smoking service, but when I offered… those
same people the choice of joining the Redpharm study, they all declined
and the reason they declined was because when they were given the
choice about being supported or not supported, they didn’t want to take
the risk, of being not supported.” PH06
“the reason [that we had difficulty recruiting] I think is it’s a very highly
ethnic area and English language isn’t number one medium so with the
paper work and the whole bulk that came with it, it was very difficult to
explain it to them how the programme worked. So we had initial interest
but then nobody carried on… when I explained it further they weren’t
really interested because of the technicalities of it…English isn’t their
number one language…to explain something that is fairly complex to
them it took my time and takes their time …I know trials you have all
these technicalities that have to be followed but if it was the programme
though we could just go straight into it without the issues surrounding it I
think it would work definitely… I did try and recruit, well the initial
recruitment as in speaking to them and I also offered them our PCT
programme [cessation], which is the standard 12 week programme and
they’d rather go for that one.” PH08
“Once you get about eight, nine people on it, it’s… too… time consuming,
if it’s..a simple thing just filling the chart, sign it, away you go, it would’ve
been easier for me. But… to keep you in behavioural support or, getting
people in, saying look how’s it going,…it was time consuming….it just
meant that I had to cap the number of people I could take on” PH07
Table 6 Barriers to recruitment and continued engagement –
illustrative quotes from pharmacists (Continued)
“people didn’t have the understanding that it’s not offered everywhere, a lot
of them thought, oh, we’ll go down road and we’ll do it there, or we’ll go
closer to home and do it there… and a lot of them… whenever you hear
research they think, oh we’re guinea pigs, what’s going happen are you
going to give us special drugs, but apart from that, which was a small
portion, there wasn’t any problems” PH0
“If you give people the choice between stopping smoking and reduction,
they want to stop.” PH10
“The, paperwork is a problem to pharmacists. It’s a bit long and it takes a
little long to fill…we’d rather to do it immediately you may try to give
someone an appointment to come the next day, in doing so that person
may not come so you may end up losing that, and that’s where I find a
little bit of a problem. We’d like a shorter level–I know you’re going to
collect statistics but, we have to think of a better way to be, to have less
paperwork…I think the level of education of most people… possibly was
not sufficient for them to understand in detail what this programme was
doing to them…There is a big document…in the beginning, and there
were, for the patient, the bigger documents that they signed in the
beginning, I think some of them don’t like to sign documents, that’s
another thing” PH10
“I mean, once they starting losing interest that was it, you know, even the
behavioural support people, they would…once they got past the initial
appointments, they were just coming in every so and so just to get patches
and it’s just one of those things. I think they felt that they weren’t doing
anything like on the programme or something…They started off well and
after three to four weeks…it just went back up…they would come in and
say, “Oh, we’re going to try and do this.” …but then they just go back to
normal and then they wouldn’t turn up. So, they start at a level, they go
down for a few weeks and then they go back up and then just disappear.“
PH04
“a lot of people left half way because maybe they didn’t see the point, or
they didn’t understand the forms that they had to fill, and I can
understand but most of them they’d not finished completely so only for
four weeks, after that they were tired and they stopped. I have time for
them when they come to the pharmacy, but I haven’t got time to start
making phone calls” PH10
“when we mentioned to them it’s a year programme… they were a bit
reluctant, initially when we say to them, look this is a good programme,
you don’t have to quit…straight away, it’s a gradual process so they were
impressed it, and then when I gave the information of the little bits, the
first, will be about forty five minutes and then it’s for a year you have to
really be committed to this programme, then they become reluctant, but
the four people I talked to, who’d really benefit from it, they just declined
on this, principle… if you were to roll this programme out you probably
might need to reduce the number of questions that have been asked, and
the… timeframe of the first session, probably needs … at least, fifteen
minutes reduction. I think you can get comfortably half an hour somebody
come to sit with you, but I think… then, it’s become like a barrier for them,
for us to get them to sit twenty minutes in the first session when we do
other stop smoking services, it’s already a task….so…”PH12
“after talking to the clients, all gave me that reason is that, this first
interview’s too long for us and, we can’t give that much time. And, the
other problem is, a lot of the clients here, their English is not, fluent
English… we have to speak in their own languages, either in Bengali or,
Urdu like that so that’s become, little bit hard.”PH12
“…because we’re offering a smoking cessation scheme as well …I’d give
them the option… about which one they wanted to go for, and they all
seemed to go for the cessation scheme rather than the reduction scheme,
so … didn’t really seem to work over here very well.” PH15
“The cessation scheme is quite straightforward, there’s a bit of paper, the
patient comes in, you take a quick… CO reading, you discuss the plan
with them, and they just literally come in week in week out to collect their
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Length and complexity of initial consultation
Pharmacists all felt that the length of the initial appoint-
ment and the complexity of the paperwork were major
barriers to recruitment. This, in the pharmacists view,
had put patients off becoming involved in the
programme, and some pharmacists also indicated that it
had deterred them from recruiting. In particular, they
felt time was wasted if participants didn’t return for sub-
sequent appointments. Although pharmacists acknowl-
edged that the length and the complexity of the first
appointment was necessary to administer the research
requirements of the programme (i.e. assess eligibility, en-
sure informed consent, and randomisation), they com-
pared the requirements to administering the smoking
cessation programme which was considered to be more
straightforward.
Understanding of research
Some pharmacists also felt that patients didn’t under-
stand, or were not prepared to accept, random allocation
to a treatment condition. In particular, pharmacists felt
that patients did not want to “take the risk” of being
assigned to self-help. Some pharmacists felt concerned
that patients would feel suspicious of the research
process, feeling that they were being experimented on
and that this might put them off wanting to take part.
Some pharmacists also suspected that patients did not
understand that this programme was not widely avail-
able and that this was an experiment. As a result, they
felt that people did not understand the imperative to
enrol straightaway.
Length, complexity and administration of the programme
Pharmacists felt that an important reason that pa-
tients chose the cessation programme over the re-
duction programme was because the former was
simpler, shorter and more familiar to patients. Phar-
macists felt that patients didn’t want to reduce over
months, but were motivated to make more immedi-
ate changes. Some pharmacists decided not to re-
cruit their quota of 16 because they did not have the
staff time available. The length of the programme,
and also the complexity and amount of paperwork
involved were also perceived to be barriers in main-
taining enthusiasm for the programme. Pharmacists
reported that some patients were deterred by having
to sign consent forms to participate in the trial and
they found it difficult to comprehend the whole
programme. This was particularly highlighted to be a
barrier for patients whose first language was not
English and those of lower educational level. Phar-
macists acknowledged that the administration in-
volved was necessary to fulfil research requirements,
but felt that if such a programme was to be imple-
mented it should be administered in a similar way to
the cessation programme.
Qualitative process measures - participants (Table 7)
Five participants were interviewed about their experi-
ence of taking part in the programme (Table 8). All par-
ticipants were motivated to quit when they joined the
programme, and had either approached the pharmacists
because they wanted to stop smoking or the pharmacist
had approached them because of a history of struggling
to quit or they were buying patches from the pharmacy.
The offer of taking part in the programme increased par-
ticipants’ motivation to try and quit, as it presented
them with an opportunity to do so. One participant also
noted that they had found answering the questions on
the accompanying forms motivating.
These five participants were generally positive about
the programme and reported that it had been helpful.
Specific aspects of the programme highlighted were the
length of time that NRT was available at minimal cost,
support from the pharmacist and CO monitoring. They
had no changes to suggest to its content or format and
reported that they would recommend the programme to
others. One exception was a participant in the self-help
arm who was not happy to be just given “assignments”.
However, he also had no changes to suggest and al-
though he was unsuccessful felt that this was just one of
many approaches he had tried that didn’t work.
Generally, there was little evidence that the partici-
pants viewed the reduction programme as being
fundamentally different to standard stop smoking pro-
grammes. The programme was seen as another oppor-
tunity to try and quit, and participants did not hold
strong opinions that being able to gradually reduce was
crucial to success. Rather than strictly following the
schedule of the programme, participants who had suc-
cessfully quit reported that they used the NRT to either
quit abruptly or rapidly reduce to quitting. Others had
tried to follow the reduction schedules, but there was
also a suggestion this hadn’t been done strictly.
Table 6 Barriers to recruitment and continued engagement –
illustrative quotes from pharmacists (Continued)
NRT, keep an eye on them… I never really got to have a good, chance
with the reduction scheme, but it looked complicated from the outset,
that’s my initial view… it’s a randomised trial isn’t it…so obviously, it can’t
be as straight forward as a cessation scheme but because of its nature I
guess, it just seemed extremely complicated from the outset.” PH15
“they were..like, oh we’re here to stop, but we want a nine month course,
and we want your support. And it’s like, well we can’t always, it depends, if
you get that, in a raffle, kind of way. And a lot of people say, oh well we’ll
go on another one then ’cause, eight to ten weeks we can do that, so we
had a lot of problems with that especially around this area, with people
didn’t understand that.” PH16
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Quantitative efficacy measures
Smoking cessation outcomes
Ten participants (one behavioural/standard, three self-
help/standard, two behavioural/short, four self-help/
short) transferred onto a smoking cessation programme,
and set a quit date. Six of these sustained abstinence for
four weeks but all had relapsed by six months after their
quit date (Tables 9 and 10). One of the six 4 week ab-
stainers was biochemically verified by exhaled CO. There
was no difference in the rate of self-report four-week
abstinence in the short programme compared with
standard length (RR 95%CI 1.00 (0.24, 4.10)) and a non-
significant 56% reduction in floating four-week abstin-
ence with behavioural support compared with self-help
(RR 95%CI 0.44 (0.10, 1.95)). The corresponding odds
ratios (95%CIs) from the generalised linear mixed model
were 1.05 (0.20, 6.00) and 0.48 (0.09, 2.69).
Smoking reduction outcomes
Six participants smoked fewer cigarettes between months
9–12 than at baseline, four of whom reduced to less than
50% of baseline consumption. There was a non-significant
two-fold increase in any sustained reduction in partici-
pants in the short length programme compared with
standard length (RR 95%CI 2.00 (0.46, 8.92) or with the
random effects model OR 2.51 (0.33, 19.11)) and a non-
significant 78% increase with behavioural support com-
pared with self-help (RR 95%CI 1.78 (0.41, 7.97) or with
the random effects model OR 3.05 (0.38, 24.76)). Similarly,
there was a non-significant increase in >50% sustained ab-
stinence in the short programme compared with standard
length, and a non-significant increase with behavioural
support compared with self-help ((RR 95% CI 3.00 (0.45,
20.44) and OR 3.05 (0.38, 24.76)) and RR 95% CI 2.67
(0.40, 18.19) and OR 2.51 (0.33, 19.11) respectively).
Discussion
There was strong evidence that a future trial of this kind
of intervention would be unfeasible. It proved hard to
recruit as intended, using naturally occurring conversa-
tions in a pharmacy, and asking doctors to write to pa-
tients that smoked and offer the pharmacy service did
little to change this. Even though pharmacists felt the
programme could potentially support smokers who find
it difficult to quit, they became largely disengaged with
the study, partly for reasons related to the trial docu-
mentation and partly that they were not comfortable
Table 7 Main themes and illustrative quotes arising from
interviews with participants
Recruitment
“[The pharmacist] knew that I smoke anyway. So, he just suggested it to
me as an idea, because I always buy patches from the pharmacy. So, he
goes “Why not do it this way, because it would save you money and it
would help you as well.” PPT1
“I went in and asked him because he got the thing on the door…
about quitting there and to ask for advice there. And, I asked him. And,
he says, “I’ll put your name down.”…And, that was it. And, it just sort of
picked up from there.” PPT2
"Normally, what it is with these local chemists, they always have
programmes running. And, I’ve been with him once before or twice
before, I think, previously. But, he knows that I give in to temptation
very quickly – the smoking part of it…I felt happy [that he offered me
the programme], because …it’s actually not just like a face behind the
counter…just give the medication and that’s it. He actually showed
concern.” PPT3
“I [saw] the sign outside, I was sort of interested myself anyway” PPT4
“I was asked because I’ve been buying patches and stuff previously. So
they obviously knew that I was trying to give up.” PPT5
Reactions to the programme
“It was overall a good experience being on it because …I was buying
patches before privately and they were costing too much. So, obviously
when I found out about this scheme, it’s a one-off payment and then
you’ve got like nine months as a free course thing so I took part of it
and it did actually help me progress quite well actually. I’d been on 8
weekly programmes before, you see, and they haven't been successful.
Whereas, this one …it’s got more time for me to quit…or to reduce,
either way” PPT1
“Do you think that the programme worked for you overall? Yeah, it
did. …and why was that? Well, you know, it just did. We just made our
minds up well I did. And, I just stopped.”PPT2
“Do you think that the programme worked for you? It has. It actually
made a lot of great improvement for myself. Again, I’ve cut down. Sadly,
I haven’t completely quit but, I have actually cut down to between 2–3
a day; now, to maybe once every 2 days……and that’s without any
patches or anything. So that’s actually… worked for me. It’s like I have a
bit more…like a stronger hold on it.” PPT3
“Did you find it helpful that you didn’t have to stop completely? I did
stop completely. The thing was I did stop completely, I didn’t sort of go
smoke and…because, you were allowed to have a certain amount of
cigarettes a week. But, from Day 1, I sort of went cold turkey and used
the patches. And, I didn’t smoke.“PPT4
Motivation
“Did the offer to join the programme…increase or affect your
motivation in any way to try and quit or reduce your smoking?
Increased it, because I knew that it was there in place and I could take
part in it. I had an opportunity so I worked for it… PPT1
“You’ve got some support, haven’t you? If you tried to do it on your
own, you’ve got no support. Whereas, if you’re doing it like with… any
pharmacy… you start to get educated. You could go in and have a
chat and you’d get it all sorted…. It gives you, you know, another
incentive to keep going.”PPT2
“It’s monitored on a weekly basis. Yeah, that was an incentive really. It’s
monitored. Normally, the other ones don’t really get monitored. It gives
you a greater incentive to not to smoke. And, especially, when you see
the carbon coming down and down every week or when it hits zero”
PPT4
“When you first joined the programme, did it help your motivation?
They did a bit, yeah, of course, you’d have to go through all the process
of filling in forms… and talking about it and they ask you all the necessary
Table 7 Main themes and illustrative quotes arising from
interviews with participants (Continued)
questions … “What have you tried and have you tried this or have you
tried that?” And all the details about how you manage…with those things
that you tried and I thought, “Oh, yeah, I will give it another go.” But it
didn’t last long, I’m afraid, now” PPT5
Farley et al. BMC Public Health  (2017) 17:210 Page 12 of 15
with randomising participants. They also saw abrupt ces-
sation as a better goal and one they were more comfort-
able supporting and were very motivated to provide
smoking cessation and reduction support to their clients.
Participants too seemed not to welcome the opportunity
to reduce as such, rather they saw it as a means of
achieving abstinence or preferred a very short reduction
phase. Most participants dropped out of treatment after
the first month or two with only a few following the
treatment programme through the full nine months.
Follow-up of participants as part of the trial procedure
using the internet was almost never successful and
follow-up by telephone became unsuccessful as partici-
pants dropped out of the programme. There was no evi-
dence that either more rapid reduction or behavioural
support improved the rate of abstinence or of reduction,
but the effect estimates were imprecise.
There were several important strengths of the trial.
The first is that we developed intervention programmes
based on existing evidence of effectiveness of smoking
reduction programmes. The evidence on NRT was clear
[4, 5], but the evidence that behavioural support was
effective is less clear and the evidence that shorter pro-
grammes are more effective is similarly uncertain [7].
That said, it appears that following a structured
programme enhances the reduction and cessation so we
developed easy to use methods and tools to support
people doing this at home. We developed a well-
received training programme for training pharmacists
and judged that all of them were competent after com-
pleting it. We supported pharmacists in delivering this
new programme and in the processes of the trial. We
also developed a comprehensive plan to evaluate several
aspects of implementing this trial [13] and produced
clear-cut results as a consequence.
There were some limitations of the trial. Key staff at
our research centre left during the course of the trial,
which meant that our support programme was perhaps
not as rigorous as it might have been. In addition, there
were technical problems with the trial database, which
meant that follow-up was not as rigorous as it might
have been. We completed fewer interviews than
Table 8 Participants characteristics
ID Treatment Gender Smoking status How recruited
PPT1 Standard/ Self-help F Quit on the programme but had
relapsed by time of interview
Known smoker to pharmacist – pharmacist
asked if she wanted to join the programme
PPT2 Standard/ Behavioural F Quit on the programme and still
abstinent at interview
Saw the poster advertising programme to
quit and asked to be enrolled
PPT3 Standard/ Self-help M Reduced on the programme, and
this was maintained at interview
Known smoker to pharmacist – pharmacist
asked if she wanted to join the programme
PPT4 Short/Behavioural M Quit on the programme and still
abstinent at interview
Saw the poster advertising programme to
quit and asked to be enrolled
PPT5 Short/Self-help M Unsuccessful Known smoker to pharmacist – pharmacist
asked if she wanted to join the programme
Table 9 Reduction and cessation outcomes for short length programme compared to standard length programme
Outcome Short length
programme
(n = 34)
Standard length
programme
(n = 34)
RR (95%CI) RD (95% CI)
Any sustained reduction (n) 4 2 2.00 (0.46, 8.95) 0.06 (−0.09, 0.22)
>50% sustained reduction (n) 3 1 3.00 (0.45, 20.44) 0.06 (−0.07, 0.20)
Floating 4 week cessation (n) 3 3 1.00 (0.24, 4.10) 0.00 (−0.16, 0.16)
Floating 6 months cessation (n) 0 0 N/A N/A
Mean difference (SD) P
Mean (SD) change in cpd baseline –
12 months (baseline carried forward)
−2.29 (7.9) −2.26 (5.4) −0.03 (1.65) 0.98
Mean (SD) change in cpd baseline –
12 months (last observation carried forward)
−6.24 (8.81) −8.41 (9.22) 2.17 (2.19) 0.32
Median (range) change in cpd baseline –
12 months (baseline carried forward)
0 (−30, 20) 0 (−20, 0)
Median (range) change in cpd baseline –
12 months (last observation carried forward)
−5 (−30, 20) −8 (−35, 18)
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anticipated and it could well be that, in particular, we
did not obtain a comprehensive picture of the range
of views. That said, it is clear to us that the lack of
enthusiasm of potential participants and pharmacists
was as a result of trying to implement the pro-
grammes as intended, rather than difficulties arising
from the support provided by the trial team. The trial
itself was potentially underpowered to detect effects
on abstinence and reduction of the size we might
have anticipated, though this was always a secondary
concern compared with the aim of assessing feasibil-
ity. However, having failed to recruit the requisite
number of participants, the trial provides little direct
evidence on the relative effectiveness of behavioural
support or speed of reduction in smoking reduction
programmes.
These results have implications for public health
research and practice. This trial took place in inner-
city Birmingham, one of the most socioeconomically
deprived areas of England. It appears that, at least in
the context of a socioeconomically deprived inner-
city, smoking reduction programmes supported by
nicotine replacement are not popular with potential
users. Feedback from both pharmacists and smokers
suggested that they preferred very rapid reduction
programmes focused on a short-term reduction goal
with cessation clearly intended. Since this trial
started, smoking reduction using electronic cigarettes
has become very popular [17], though largely unsup-
ported by health professionals such as pharmacists,
as we tried here. The results may have implications
for trials with pharmacists. It was clear here that
some were unprepared to randomise participants or
ignored the randomisation and provided what they
thought was best interest of their patients. Many
others expressed concern about randomisation to
self-help. We had tried to counter this by providing
training about the basis for randomisation and why
it was important for proving what the pharmacists
might believe to be true, but it was clear this train-
ing failed in some cases. Future trials in any context
may need to pay particular attention to assessing
equipoise and further training on this point as well
as closer supervision, which, this trial shows, cannot
be taken for granted.
Although this trial met with difficulties in recruit-
ing, randomising, and delivering care, other trials
based in pharmacies have had much greater success
in these areas. A systematic review of pharmacy deliv-
ered public health programmes testing the effective-
ness of interventions on smoking, excess alcohol
consumption, and weight loss programmes found 19
studies including 12 randomised trials [18]. Generally,
these programmes ran well without problems enacting
randomisation and recruited to target. There was
clear evidence that, compared with no intervention,
pharmacy-delivered smoking cessation support was
effective but no evidence it was more effective than
other active cessation support interventions. The poor
enactment of this trial may reflect both pharmacists’
and members of the public’s lukewarm reaction to
smoking reduction. A series of pilots of new models
of smoking cessation support that offered smoking re-
duction programmes in the NHS resulted in low up-
take, with nearly all service users opting for abrupt
cessation, even among groups such as people on
methadone maintenance programmes [19]. Thus, it
appears that part of the failure of this programme re-
lated to the aim of delivering a smoking reduction
programme, which few people wanted.
Table 10 Reduction and cessation outcomes for behavioural support compared to self-help
Outcome Behavioural support
(n = 36)
Self - help
(n = 32)
RR (95% CI) RD (95% CI)
Any sustained reduction (n) 4 2 1.78 (0.41, 7.97) 0.05 (−0.11, 0.2)
>50% sustained reduction (n) 3 1 2.67 (0.4, 18.19) 0.05 (−0.09, 0.19)
Floating 4 week cessation (n) 2 4 0.44 (0.10, 1.95) −0.07 (−0.24, 0.08)
Floating 6 months cessation (n) 0 0 N/A N/A
Mean difference (SD) P
Mean (SD) change in cpd baseline –
12 months (baseline carried forward)
−1.58 (7.2) −3.36 (6.14) 1.48 (1.64) 0.37
Mean (SD) change in cpd baseline –
12 months (last observation carried forward)
−7.31 (8.98) −7.34 (9.21) 0.04 (2.21) 0.98
Median (range) change in cpd baseline –
12 months (baseline carried forward)
0 (−30, 20) 0 (−21, 0)
Median (range) change in cpd baseline –
12 months (last observation carried forward)
−5.5 (−30, 20) −7 (−35, 18)
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Conclusion
Pharmacists were willing to support patients to reduce
their smoking in theory, but a well-designed training
programme failed to motivate pharmacists to deliver the
programme as intended. Opportunistic identification of
potential participants by pharmacists, with additional
advertisement to smokers by GPs did not result in at-
tainment of the recruitment target. This programme as
implemented is not feasible in routine practice at phar-
macies and suggests that short and simple programmes
would be more readily engaged with in this context.
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